Barclays analyst Matt Miksic raised the firm’s price target on LivaNova to $61 from $57 and keeps an Equal Weight rating on the shares. The analyst updated sales estimates to reflect the wind-down of the ACS business, offset by upside in Neuromod.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LIVN: